ZOLL Medical Singapore Wins SBR International Business Award for Health Technology

The company has been recognized for its innovation in the medical field.

To complement hospital resuscitation protocols and provide early defibrillation to at-risk patients, ZOLL Medical Asia Pacific launched the Hospital Portable Defibrillator (HWD) in 2021 in Thailand, Malaysia and Singapore.

The HWD is the world’s first and only wearable defibrillator developed for hospital use for the continued protection of patients at risk of sudden cardiac death.

Worldwide, sudden and unexpected cardiac death is the most common cause of death, accounting for 17 million deaths each year, with SCD accounting for 25% of those.¹

Whereas as data on incidence and survival after in-hospital cardiac arrest are still limited, most studies report an incidence of one to six such events per 1000 hospitalizations. Treatment and survival remain a challenge: only 12-25% survive.²

Of course, for these at-risk patients, every minute counts, and prompt treatment of patients at risk of sudden cardiac death can mean the difference between neurologically intact survival or, for survivors, something less.

The HWD quickly detects and automatically defibrillates patients to restore a normal heart rhythm. In a typical situation, the entire event, from the moment the HWD detects a rapid, life-threatening heartbeat to the automatic delivery of a treatment shock, occurs in approximately one minute. When the heart can quickly regain a perfusing rhythm, long-term complications can be minimized.

Since its launch in February 2021, the HWD has been adopted by six hospitals in Malaysia and Thailand and has successfully protected dozens of patients in Malaysia and Thailand.

“HWD provides much-needed protection for patients who may need defibrillation therapy in the event of heart rhythm failure, when treated in a non-critical unit. Immediate treatment or shock therapy is important for patients with sudden cardiac arrest because every minute is wasted increases the risk of death by another ten percent.” Dr Abdul Raqib, a consultant cardiologist at Serdang Hospital in Malaysia, said.

ZOLL Medical Asia Pacific plans to expand the technology’s availability to more Asia-Pacific countries and seeks to continue to work hand-in-hand with healthcare professionals and hospitals to identify and protect at-risk hospital patients. some CDS.

For these, the company has been honored with the SBR International Business Awards in Health Technology. The awards program, presented by Singapore Business Reviewrecognizes outstanding projects by foreign companies in Singapore.


1. https://www.aerjournal.com/articles/sudden-cardiac-death-and-arrhythmias

2. https://www.bmj.com/content/367/bmj.l6373

Watch the interview below to learn more about their winning project:

Comments are closed.